836 related articles for article (PubMed ID: 24874200)
1. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction.
Bello NA; Claggett B; Desai AS; McMurray JJ; Granger CB; Yusuf S; Swedberg K; Pfeffer MA; Solomon SD
Circ Heart Fail; 2014 Jul; 7(4):590-5. PubMed ID: 24874200
[TBL] [Abstract][Full Text] [Related]
2. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
Lund LH; Claggett B; Liu J; Lam CS; Jhund PS; Rosano GM; Swedberg K; Yusuf S; Granger CB; Pfeffer MA; McMurray JJV; Solomon SD
Eur J Heart Fail; 2018 Aug; 20(8):1230-1239. PubMed ID: 29431256
[TBL] [Abstract][Full Text] [Related]
3. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
4. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
Kristensen SL; Køber L; Jhund PS; Solomon SD; Kjekshus J; McKelvie RS; Zile MR; Granger CB; Wikstrand J; Komajda M; Carson PE; Pfeffer MA; Swedberg K; Wedel H; Yusuf S; McMurray JJ
Circulation; 2015 Jan; 131(1):43-53. PubMed ID: 25406306
[TBL] [Abstract][Full Text] [Related]
5. Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction.
Park CS; Park JJ; Mebazaa A; Oh IY; Park HA; Cho HJ; Lee HY; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
J Am Heart Assoc; 2019 Mar; 8(6):e011077. PubMed ID: 30845873
[TBL] [Abstract][Full Text] [Related]
6. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM
J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249
[TBL] [Abstract][Full Text] [Related]
8. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
9. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
Wolsk E; Claggett B; Køber L; Pocock S; Yusuf S; Swedberg K; McMurray JJV; Granger CB; Pfeffer MA; Solomon SD
Eur J Heart Fail; 2018 Mar; 20(3):504-510. PubMed ID: 29193462
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
11. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction.
Desai AS; Claggett B; Pfeffer MA; Bello N; Finn PV; Granger CB; McMurray JJ; Pocock S; Swedberg K; Yusuf S; Solomon SD
Circ Heart Fail; 2014 Nov; 7(6):895-902. PubMed ID: 25326006
[TBL] [Abstract][Full Text] [Related]
12. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Solomon SD; Dobson J; Pocock S; Skali H; McMurray JJ; Granger CB; Yusuf S; Swedberg K; Young JB; Michelson EL; Pfeffer MA;
Circulation; 2007 Sep; 116(13):1482-7. PubMed ID: 17724259
[TBL] [Abstract][Full Text] [Related]
13. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
Berg DD; Jhund PS; Docherty KF; Murphy SA; Verma S; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sjöstrand M; Solomon SD; McMurray JJV; Sabatine MS
JAMA Cardiol; 2021 May; 6(5):499-507. PubMed ID: 33595593
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction.
Shin SH; Claggett B; Inciardi RM; Santos ABS; Shah SJ; Zile MR; Pfeffer MA; Shah AM; Solomon SD
J Am Heart Assoc; 2021 Aug; 10(15):e019545. PubMed ID: 34325519
[TBL] [Abstract][Full Text] [Related]
15. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
Haass M; Kitzman DW; Anand IS; Miller A; Zile MR; Massie BM; Carson PE
Circ Heart Fail; 2011 May; 4(3):324-31. PubMed ID: 21350053
[TBL] [Abstract][Full Text] [Related]
16. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
Cunningham JW; Vaduganathan M; Claggett BL; John JE; Desai AS; Lewis EF; Zile MR; Carson P; Jhund PS; Kober L; Pitt B; Shah SJ; Swedberg K; Anand IS; Yusuf S; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2020 Aug; 8(8):618-626. PubMed ID: 32387067
[TBL] [Abstract][Full Text] [Related]
17. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
Shah RV; Desai AS; Givertz MM
J Card Fail; 2010 Mar; 16(3):260-7. PubMed ID: 20206902
[TBL] [Abstract][Full Text] [Related]
18. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.
Yap J; Tay WT; Teng TK; Anand I; Richards AM; Ling LH; MacDonald MR; Chandramouli C; Tromp J; Siswanto BB; ; Zile M; McMurray J; Lam CSP
J Am Heart Assoc; 2019 Sep; 8(17):e013114. PubMed ID: 31431116
[TBL] [Abstract][Full Text] [Related]
19. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
[TBL] [Abstract][Full Text] [Related]
20. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]